Hyperthyroidism under the microscope: evolving management

Hyperthyroidism affects up to 2.5% of adults globally, presenting as either overt or subclinical disease with wide-ranging systemic effects. Graves’ disease remains the leading cause in iodine-sufficient regions, while toxic nodular disease is more prevalent in iodine-deficient populations. Clinical manifestations vary from classic signs like weight loss, anxiety, and palpitations to subtle symptoms in older adults. The diagnostic workup combines hormonal assays, antibody testing, and imaging—strategies essential for distinguishing Graves’ disease from thyroiditis or exogenous thyrotoxicosis. Special considerations include drug interference (e.g., biotin), COVID-19-associated thyroid dysfunction, and immune checkpoint inhibitor-related cases.

Management of hyperthyroidism hinges on etiology and patient-specific factors. Antithyroid drugs such as methimazole and propylthiouracil are first-line treatments, particularly for Graves’ disease. While effective, they carry a risk of side effects like agranulocytosis and hepatotoxicity. Radioactive iodine ablation offers a non-invasive alternative but is linked to exacerbation of thyroid eye disease and possible long-term oncologic risks. Thyroidectomy remains definitive but is often reserved for patients with large goiters, suspected malignancy, or severe ophthalmopathy. For select cases of toxic nodules, minimally invasive techniques like radiofrequency ablation are emerging as viable options.

Subclinical hyperthyroidism, though often asymptomatic, increases the risk of atrial fibrillation, osteoporosis, and mortality—particularly when TSH falls below 0.1 mIU/L. The decision to treat is nuanced and should be individualized based on age, comorbidities, and disease trajectory. Meanwhile, in pregnancy, careful antithyroid drug use and timing of interventions are essential to minimize fetal risk.

As thyroid disease intersects with new medical technologies, oncology treatments, and shifting epidemiology, clinicians must stay agile in their diagnostic and therapeutic approaches. In a world of rising endocrine disorders, sharing this knowledge may help empower both practitioners and patients to navigate the complexities of hyperthyroidism more effectively.